Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

David Wild

Reporter

Toronto, Canada
David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.

Latest From David Wild

Podcast: Improving Communication – The Relationship Between Biotech And Pharma

Bookmark
  • Interviews
By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Financing Deals

The Biotech Balancing Act: Long-Term Vision Vs. Inflection Points

Bookmark
  • Interviews
By David Wild

Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech. 

Rising Leaders Gene Therapy

BioBytes: AI-Related Deals In Q2 2024

Bookmark
  • Analysis
By David Wild

Dominated by Xaira Therapeutics' $1bn venture financing, Q2 2024 was also notable for sizeable public offerings by Alumis and Recursion Therapeutics in the US and XtalPi Technology in Hong Kong, as well as a $142m seed round for EvolutionaryScale.   

Market Intelligence Deals

Poland’s Quiet Pivot From Generics To Innovative Treatments

Bookmark
  • Analysis
By David Wild

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

Poland Emerging Markets

Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment

Bookmark
  • Interviews
By David Wild

Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.

Innovation Platform Technologies

A GenAI Copilot For The Regulatory Affairs Team

Bookmark
  • News
By David Wild

A GenAI copilot for biopharma regulatory requirements could yield significant returns.

Artificial Intelligence Regulatory
See All
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By